PMC:7195088 / 44985-45576 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1329","span":{"begin":89,"end":94},"obj":"Species"},{"id":"1330","span":{"begin":133,"end":146},"obj":"Species"},{"id":"1331","span":{"begin":148,"end":158},"obj":"Species"},{"id":"1332","span":{"begin":160,"end":168},"obj":"Species"},{"id":"1333","span":{"begin":175,"end":183},"obj":"Species"},{"id":"1334","span":{"begin":320,"end":328},"obj":"Species"},{"id":"1335","span":{"begin":0,"end":10},"obj":"Chemical"},{"id":"1336","span":{"begin":458,"end":468},"obj":"Chemical"},{"id":"1337","span":{"begin":311,"end":319},"obj":"Disease"}],"attributes":[{"id":"A1329","pred":"tao:has_database_id","subj":"1329","obj":"Tax:1570291"},{"id":"A1330","pred":"tao:has_database_id","subj":"1330","obj":"Tax:11118"},{"id":"A1331","pred":"tao:has_database_id","subj":"1331","obj":"Tax:2697049"},{"id":"A1332","pred":"tao:has_database_id","subj":"1332","obj":"Tax:694009"},{"id":"A1333","pred":"tao:has_database_id","subj":"1333","obj":"Tax:1335626"},{"id":"A1334","pred":"tao:has_database_id","subj":"1334","obj":"Tax:9606"},{"id":"A1335","pred":"tao:has_database_id","subj":"1335","obj":"MESH:C000606551"},{"id":"A1336","pred":"tao:has_database_id","subj":"1336","obj":"MESH:C000606551"},{"id":"A1337","pred":"tao:has_database_id","subj":"1337","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Remdesivir is an investigational nucleotide analogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only within strictly regulated and limited compassionate-use/expanded-access frameworks."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T82","span":{"begin":33,"end":43},"obj":"Body_part"}],"attributes":[{"id":"A82","pred":"fma_id","subj":"T82","obj":"http://purl.org/sig/ont/fma/fma82740"}],"text":"Remdesivir is an investigational nucleotide analogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only within strictly regulated and limited compassionate-use/expanded-access frameworks."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T246","span":{"begin":89,"end":94},"obj":"Disease"},{"id":"T247","span":{"begin":148,"end":156},"obj":"Disease"},{"id":"T248","span":{"begin":160,"end":168},"obj":"Disease"},{"id":"T249","span":{"begin":311,"end":319},"obj":"Disease"}],"attributes":[{"id":"A246","pred":"mondo_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"},{"id":"A247","pred":"mondo_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A248","pred":"mondo_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A249","pred":"mondo_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Remdesivir is an investigational nucleotide analogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only within strictly regulated and limited compassionate-use/expanded-access frameworks."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T263","span":{"begin":116,"end":124},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T264","span":{"begin":211,"end":217},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"}],"text":"Remdesivir is an investigational nucleotide analogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only within strictly regulated and limited compassionate-use/expanded-access frameworks."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T550","span":{"begin":33,"end":43},"obj":"Chemical"},{"id":"T551","span":{"begin":442,"end":446},"obj":"Chemical"},{"id":"T552","span":{"begin":458,"end":468},"obj":"Chemical"}],"attributes":[{"id":"A550","pred":"chebi_id","subj":"T550","obj":"http://purl.obolibrary.org/obo/CHEBI_36976"},{"id":"A551","pred":"chebi_id","subj":"T551","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A552","pred":"chebi_id","subj":"T552","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"Remdesivir is an investigational nucleotide analogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only within strictly regulated and limited compassionate-use/expanded-access frameworks."}

{"project":"LitCovid-sentences","denotations":[{"id":"T359","span":{"begin":0,"end":255},"obj":"Sentence"},{"id":"T360","span":{"begin":256,"end":359},"obj":"Sentence"},{"id":"T361","span":{"begin":360,"end":591},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Remdesivir is an investigational nucleotide analogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only within strictly regulated and limited compassionate-use/expanded-access frameworks."}

{"project":"2_test","denotations":[{"id":"32360444-32020029-22369764","span":{"begin":232,"end":234},"obj":"32020029"},{"id":"32360444-31924756-22369765","span":{"begin":238,"end":240},"obj":"31924756"},{"id":"32360444-32054787-22369766","span":{"begin":244,"end":246},"obj":"32054787"}],"text":"Remdesivir is an investigational nucleotide analogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only within strictly regulated and limited compassionate-use/expanded-access frameworks."}